Moleculin Biotech company info

What does Moleculin Biotech do?
Moleculin Biotech (NASDAQ:MBRX) is a dedicated biopharmaceutical company that focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses. Their research pipeline is rich with projects that aim to bring revolutionary treatments to patients worldwide, primarily focusing on leveraging small molecule drugs to target cancer cells and viral infections effectively. One of their noteworthy objectives is to advance the science of treating cancers that have proven difficult to combat with existing medications, striving to unlock new pathways to remission and improve patient outcomes. Through rigorous research, clinical trials, and strategic partnerships, Moleculin Biotech is committed to pushing the boundaries of medicine to provide new hope for patients facing cancer and other serious diseases.
Moleculin Biotech company media
Company Snapshot

Is Moleculin Biotech a public or private company?

key
Ownership
Public

How many people does Moleculin Biotech employ?

people
Employees
18

What sector is Moleculin Biotech in?

pie chart
Sector
Health Care

Where is the head office for Moleculin Biotech?

location pin
Head Office
Houston, United States

What year was Moleculin Biotech founded?

founded flag
Year Founded
2015
What does Moleculin Biotech specialise in?
/Cancer Therapeutics /Drug Development /Clinical Trials /Annamoses Program /Immunotherapy Research /Pharmaceutical Research

What are the products and/or services of Moleculin Biotech?

Overview of Moleculin Biotech offerings
Annamycin, a next-generation anthracycline designed to avoid multidrug resistance mechanisms with a focus on treating relapsed or refractory acute myeloid leukemia.
WP1066, an immune/transcription modulator targeting tumors with a focus on brain tumors and acute myeloid leukemia.
WP1122, a prodrug of 2-DG (2-deoxy-D-glucose) aimed at exploiting the metabolic differences in cancer cells to treat glioblastoma and potentially other cancers.
WP1220, a topical treatment for cutaneous T-cell lymphoma, offering a direct approach to suppress tumor growth in the skin.
WP1234, a novel compound targeting a wide range of tumors, including pancreatic cancer, through unique mechanisms of action.

Who is in the executive team of Moleculin Biotech?

Moleculin Biotech leadership team
  • Mr. Walter V. Klemp
    Mr. Walter V. Klemp
    Founder, Chairman, President & CEO
  • Mr. Jonathan P. Foster CPA
    Mr. Jonathan P. Foster CPA
    Executive VP & CFO
  • Dr. Donald H. Picker Ph.D.
    Dr. Donald H. Picker Ph.D.
    Chief Scientific Officer
  • Dr. Waldemar  Priebe Ph.D.
    Dr. Waldemar Priebe Ph.D.
    Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board
  • Dr. Robert C. Shepard FACP, M.D.
    Dr. Robert C. Shepard FACP, M.D.
    Chief Medical Officer of Annamycin
  • Dr. John Paul Waymack M.D., Sc.D.
    Dr. John Paul Waymack M.D., Sc.D.
    Senior Chief Medical Officer
  • Dr. Sandra L. Silberman M.D., Ph.D.
    Dr. Sandra L. Silberman M.D., Ph.D.
    Chief Medical Officer of New Products
  • Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D.
    Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D.
    European Chief Medical Officer